Potential lack of standing could end Myriad case with no DNA patent resolution
This article was originally published in Clinica
A lawsuit against molecular diagnostics company Myriad Genetics, concerning the thorny issue of whether isolated DNA can be patented or not, was brought before the US Court of Appeals for the Federal Circuit in Washington yesterday. However, before a ruling can be passed, the three-judge panel must first decide if the plaintiffs in the case actually have standing to bring the suit.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.